2024년에 127억 달러로 추정되는 라임병 검사 세계 시장은 2024-2030년간 CAGR 6.6%로 성장하여 2030년에는 186억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 IGRA 검사 기술은 CAGR 5.4%를 나타내고, 분석 기간 종료시에는 124억 달러에 이를 것으로 예측됩니다. 기타 기술 부문의 성장률은 분석 기간중 CAGR 9.2%로 추정됩니다.
미국 시장은 33억 달러로 추정, 중국은 CAGR6.5%로 성장 예측
미국의 라임병 검사 시장은 2024년에 33억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년 CAGR 6.5%로 성장하여 2030년까지 30억 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 5.9%와 5.7%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 5.4%를 나타낼 전망입니다.
세계의 라임병 검사 시장 - 주요 동향과 촉진요인 정리
라임병 검사의 중요성이 커지는 이유는?
라임병은 진드기가 매개하는 가장 흔한 질병 중 하나이며, 기후 변화와 유행지역에서의 야외활동 증가로 인해 환자가 증가하고 있습니다. 라임병을 조기에 정확하게 발견하는 것은 신경 및 관절 문제 등 장기적인 합병증을 예방하는 데 매우 중요합니다. 진드기 매개 질환에 대한 사회적 인식이 높아짐에 따라 고도의 신뢰도 높은 라임병 검사에 대한 수요가 증가하고 있습니다.
기술 혁신은 라임병 검사 성능을 어떻게 향상시키고 있는가?
분자진단학, 혈청학적 분석, 신속 POC 검사의 발전으로 라임병 진단의 정확성과 속도가 향상되고 있습니다. 차세대 PCR 기반 검사는 보렐리아균을 조기에 검출할 수 있어 기존 항체 검사에 따른 위음성을 줄일 수 있습니다. AI를 활용한 진단 도구와 가정용 검사 키트도 등장해 보다 신속하고 간편한 검사 솔루션을 제공합니다. 또한, 연구진은 라임병을 다른 진드기 매개 질환과 구별할 수 있는 다중 표적 분석법을 개발하고 있습니다.
시장 성장 촉진요인은?
라임병 발병률 증가, 공중보건에 대한 관심 증가, 진단법의 기술적 진보가 시장 성장 촉진요인입니다. 정부기관과 연구기관은 조기 발견과 치료 성과 향상을 위해 더 나은 진단 도구에 투자하고 있습니다. 야외 레크리에이션 활동과 반려동물 양육 증가 추세도 라임병에 대한 인식과 검사의 필요성을 높이고 있습니다.
어떤 과제와 미래 기회가 존재할까?
검사 정확도의 편차, 고도의 진단법의 높은 비용, 지역에 따라 인지도가 낮다는 점 등이 문제점으로 지적되고 있습니다. 그러나 AI를 이용한 라임병 감지 도구 개발, 가정용 검사 키트 보급, 정기 건강검진에 라임병 검진 포함 등 기회는 존재합니다.
부문
기술(IGRA 검사 기술, 기타 기술); 테스트(혈청학적 테스트, 림프구 변환 테스트, 소변 항원 테스트, 면역 형광 염색 테스트, 핵산 테스트); 샘플(혈액 샘플, 소변 샘플, CSF 샘플, 기타 샘플); 최종 용도(병원 최종 용도, 진단 실험실 최종 용도, 기타 최종 용도); 최종 용도(병원 최종 용도, 진단 실험실 최종 용도, 기타 최종 용도)
조사 대상 기업 예
Abbott Laboratories
Affymetrix, Inc.
bioMerieux SA
Bio-Rad Laboratories, Inc.
Ceres Nanosciences
DiaSorin S.p.A
F. Hoffmann-La Roche AG
Galaxy Diagnostics
Gold Standard Diagnostics
Graphene Frontiers
IGeneX, Inc.
LabCorp
Meridian Bioscience, Inc.
Oxford Immunotec
Quest Diagnostics
Quidel Corporation
T2 Biosystems, Inc.
Thermo Fisher Scientific, Inc.
Trinity Biotech
ZEUS Scientific
AI 통합
우리는 검증된 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
LSH
영문 목차
영문목차
Global Lyme Disease Testing Market to Reach US$18.6 Billion by 2030
The global market for Lyme Disease Testing estimated at US$12.7 Billion in the year 2024, is expected to reach US$18.6 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. IGRA Testing Technology, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$12.4 Billion by the end of the analysis period. Growth in the Other Technologies segment is estimated at 9.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$3.3 Billion While China is Forecast to Grow at 6.5% CAGR
The Lyme Disease Testing market in the U.S. is estimated at US$3.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.9% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.
Lyme disease is one of the most common tick-borne illnesses, with cases rising due to climate change and increased outdoor activities in endemic areas. Early and accurate detection of Lyme disease is critical to preventing long-term complications such as neurological and joint issues. As public awareness of tick-borne diseases grows, the demand for advanced and reliable Lyme disease testing is increasing.
How Are Innovations Enhancing the Performance of Lyme Disease Testing?
Advancements in molecular diagnostics, serological assays, and rapid point-of-care testing are improving the accuracy and speed of Lyme disease diagnosis. Next-generation PCR-based tests can detect the Borrelia bacteria at an early stage, reducing false negatives associated with traditional antibody tests. AI-driven diagnostic tools and at-home test kits are also emerging, providing faster and more accessible testing solutions. Additionally, researchers are developing multi-target assays that can distinguish Lyme disease from other tick-borne illnesses.
What Are the Key Market Drivers?
The rising incidence of Lyme disease, increased public health initiatives, and technological advancements in diagnostic methods are key market drivers. Government agencies and research institutions are investing in better diagnostic tools to enable early detection and improve treatment outcomes. The growing trend of outdoor recreational activities and pet ownership has also heightened the need for Lyme disease awareness and testing.
What Challenges and Future Opportunities Exist?
Challenges include the variability in test accuracy, high costs of advanced diagnostic methods, and limited awareness in some regions. However, opportunities exist in developing AI-assisted Lyme disease detection tools, expanding at-home test kit availability, and integrating Lyme disease screening into routine wellness check-ups.
SCOPE OF STUDY:
The report analyzes the Lyme Disease Testing market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Technology (IGRA Testing Technology, Other Technologies); Test (Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test, Nucleic Acid Test); Sample (Blood Sample, Urine Sample, CSF Sample, Other Samples); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 32 Featured) -
Abbott Laboratories
Affymetrix, Inc.
bioMerieux SA
Bio-Rad Laboratories, Inc.
Ceres Nanosciences
DiaSorin S.p.A
F. Hoffmann-La Roche AG
Galaxy Diagnostics
Gold Standard Diagnostics
Graphene Frontiers
IGeneX, Inc.
LabCorp
Meridian Bioscience, Inc.
Oxford Immunotec
Quest Diagnostics
Quidel Corporation
T2 Biosystems, Inc.
Thermo Fisher Scientific, Inc.
Trinity Biotech
ZEUS Scientific
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Lyme Disease Testing - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Global Incidence of Lyme Disease Throws the Spotlight on Early and Accurate Diagnostic Solutions
Increased Awareness of Tick-Borne Illnesses Spurs Demand for Preventive Testing and Screening Services
Expansion of Point-of-Care Testing Capabilities Enhances Accessibility in Rural and Underserved Areas
Advancements in Molecular and Serological Testing Methods Strengthen Diagnostic Accuracy and Speed
Growing Availability of At-Home Lyme Disease Test Kits Expands Direct-to-Consumer Market Opportunity
Government and NGO-Funded Public Health Campaigns Propel Testing Awareness and Uptake
Integration of Lyme Testing Into Routine Travel and Outdoor Health Checkups Increases Market Penetration
Increase in Outdoor Recreational Activities Post-Pandemic Drives Risk-Based Testing Demand
Regulatory Push for Standardization and Test Validation Improves Reliability Across Commercial Test Providers
Rising Clinical Interest in Co-Infections and Chronic Lyme Disease Supports Multi-Pathogen Testing Platforms
Insurance Coverage Expansion in North America Enhances Affordability and Uptake of Lyme Testing
Growth in Personalized and Preventive Medicine Accelerates Demand for Early Diagnostic Tools
Growing Concerns Over Misdiagnosis and Delayed Treatment Strengthen Business Case for Improved Test Accuracy
Adoption of AI and Predictive Analytics in Lab Testing Enhances Efficiency in Diagnosis and Reporting
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Lyme Disease Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Lyme Disease Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Lyme Disease Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Lyme Disease Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for IGRA Testing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for IGRA Testing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for IGRA Testing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for CSF Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for CSF Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for CSF Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Other Samples by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Blood Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Urine Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Serological Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Serological Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Serological Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Lymphocytic Transformation Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Lymphocytic Transformation Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Lymphocytic Transformation Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Urine Antigen Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Urine Antigen Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: World 15-Year Perspective for Urine Antigen Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Immunofluorescent Staining Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 42: World Historic Review for Immunofluorescent Staining Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: World 15-Year Perspective for Immunofluorescent Staining Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Nucleic Acid Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 45: World Historic Review for Nucleic Acid Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: World 15-Year Perspective for Nucleic Acid Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 47: USA Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: USA 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: USA Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: USA 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 53: USA Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: USA Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: USA 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 56: USA Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: USA Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: USA 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
CANADA
TABLE 59: Canada Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Canada 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 62: Canada Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Canada Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Canada 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 65: Canada Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Canada Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Canada 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 68: Canada Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Canada Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Canada 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
JAPAN
Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 71: Japan Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Japan 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 74: Japan Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Japan Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Japan 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 77: Japan Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Japan Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Japan 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 80: Japan Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Japan Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Japan 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
CHINA
Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 83: China Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: China Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: China 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 86: China Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: China Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: China 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 89: China Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: China Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: China 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 92: China Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: China Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: China 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
EUROPE
Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 95: Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 96: Europe Historic Review for Lyme Disease Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Europe 15-Year Perspective for Lyme Disease Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 98: Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Europe Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Europe 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 101: Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Europe Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Europe 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 104: Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Europe Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Europe 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 107: Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Europe Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Europe 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
FRANCE
Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 110: France Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: France Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: France 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 113: France Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: France Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: France 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 116: France Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: France Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: France 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 119: France Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: France Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: France 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
GERMANY
Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 122: Germany Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Germany Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Germany 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 125: Germany Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Germany Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Germany 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 128: Germany Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Germany Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Germany 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 131: Germany Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Germany Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Germany 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
ITALY
TABLE 134: Italy Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Italy Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Italy 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 137: Italy Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Italy Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Italy 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 140: Italy Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Italy Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Italy 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 143: Italy Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Italy Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Italy 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
UNITED KINGDOM
Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 146: UK Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: UK Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: UK 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 149: UK Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: UK Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: UK 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 152: UK Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: UK Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: UK 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 155: UK Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: UK Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: UK 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Rest of Europe Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Rest of Europe 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Rest of Europe Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Rest of Europe 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Europe Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Rest of Europe 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Rest of Europe Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Rest of Europe 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: Asia-Pacific Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: Asia-Pacific 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: Asia-Pacific Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: Asia-Pacific 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Asia-Pacific Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: Asia-Pacific 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Asia-Pacific Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: Asia-Pacific 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
REST OF WORLD
TABLE 182: Rest of World Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of World Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: Rest of World 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
TABLE 185: Rest of World Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of World Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: Rest of World 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
TABLE 188: Rest of World Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of World Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Rest of World 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 191: Rest of World Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of World Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Rest of World 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
